Dominika Wieczorek Kirk

Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study

Matthias Herz, Markolf Hanefeld, M. Hanefeld, 2014, BMC Nephrology.